Garrison Point Advisors LLC Reduces Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Garrison Point Advisors LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 38.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,125 shares of the medical instruments supplier’s stock after selling 700 shares during the quarter. Garrison Point Advisors LLC’s holdings in Becton, Dickinson and Company were worth $271,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Nordea Investment Management AB lifted its holdings in Becton, Dickinson and Company by 277.3% in the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after buying an additional 1,423,353 shares during the period. PineStone Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 141.6% in the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after acquiring an additional 788,735 shares in the last quarter. M&G Plc bought a new position in Becton, Dickinson and Company in the first quarter worth $173,692,000. First Eagle Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 32.5% in the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after acquiring an additional 688,296 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after acquiring an additional 346,720 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the subject of a number of analyst reports. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Evercore ISI lifted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Stock Down 0.8 %

BDX opened at $238.62 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $262.23. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average price of $237.33 and a 200-day moving average price of $235.16. The stock has a market capitalization of $68.96 billion, a price-to-earnings ratio of 52.56, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the business posted $2.96 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.